Product Data Sheet

Product Name: PF-07976016
Cat. No.: GC81482

Chemical Properties

Cas. No.	3059496-70-4		
Formula	$C_{28}H_{29}N_3O_4$	M.Wt	471.55
Solubility	DMSO: 50 mg/mL (106.03 mM; Need ultrasonic)	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.		
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.		

Structure



Background

Product Data Sheet

PF-07976016 (GIPR antagonist 4) is an orally active GIPR antagonist with an IC_{50} of 4.1 nM. PF-07976016 (GIPR antagonist 4) exerts its antagonistic effect by competitively binding to GIPR and blocking the increase in Gαs -mediated cAMP production induced by GIP agonists. The combination of GIPR antagonist 4 and Liraglutide can enhance the weight loss effect of the single drug. PF-07976016 (GIPR antagonist 4) can be used for research related to obesity and metabolic diseases [1].

In Vivo, In hGIPR KI mice fed a high-fat diet, GIPR antagonist 4 (30 mg/kg; oral; once daily; for 20 days) showed better weight loss in combination with Liraglutide (0.05 mg/kg; subcutaneous injection; once daily; for 20 days) than the single drug group[1].

In Vitro, PF-07976016 (GIPR antagonist 4) (0.1-40 μM; 2.5 h) showed GIPR antagonistic activity in CHO-K1 cells stably expressing the human GIPR receptor, with an IC_{50} of 4.1 nM.

References:
[1]. Dullea RG, et al. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and GLP-1 receptor agonist compounds. US20250235460 A1. July 24, 2025.

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com
Address: 10292 Central Ave. #205, Montclair, CA, USA